Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pursuing a Career in Clinical Research: When, Why, and How. Sergio Leonardi, MD, MHS Italian Cardiovascular Fellow.

Published byKasandra Billey Modified over 9 years ago

Similar presentations

Presentation on theme: "Pursuing a Career in Clinical Research: When, Why, and How. Sergio Leonardi, MD, MHS Italian Cardiovascular Fellow."— Presentation transcript:

1

2 Pursuing a Career in Clinical Research: When, Why, and How. Sergio Leonardi, MD, MHS Italian Cardiovascular Fellow

3 All Rights Reserved, Duke Medicine 2007 DUKE University One of the most prestigious Universities of the United States Duke Heart Center consistently ranked among the top 10 heart centers in the United States in the last 10 years

4 All Rights Reserved, Duke Medicine 2007 DUKE in Durham, North Carolina The Chapel, symbol of Duke Durham, NC

5 All Rights Reserved, Duke Medicine 2007 North Pavilion 846 Faculty and Staff Durham Centre 288 Faculty and Staff Hock Plaza Statistical Faculty 5

6 All Rights Reserved, Duke Medicine 2007 Standard Medical Therapy Vorapaxar 40 mg + 2.5 mg/d Placebo 1  EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc 2  EP: CV Death/MI/stroke Double-blind Non-ST-Segment Elevation ACS N=12,500 Follow-Up Day 30; 4, 8, 12 Months; Every 6 months after 1st year Final Visit 1:1

7 All Rights Reserved, Duke Medicine 2007 Orlando, FL LBCT Session Sunday November 13 th 2011 h. 16.52

8 All Rights Reserved, Duke Medicine 2007 Contact Info Sergio Leonardi sergio.leonardi@duke.edu

Download ppt "Pursuing a Career in Clinical Research: When, Why, and How. Sergio Leonardi, MD, MHS Italian Cardiovascular Fellow."

Similar presentations

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.
Standard Medical Therapy TRA 40 mg + 2.5 mg/d TRA 40 mg + 2.5 mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.

Standard Medical Therapy TRA 40 mg mg/d TRA 40 mg mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.

Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Bringing Together Training Programs, Title V, and Families for Leadership Development University of North Carolina MCH Leadership Consortium Kathleen Rounds.

Bringing Together Training Programs, Title V, and Families for Leadership Development University of North Carolina MCH Leadership Consortium Kathleen Rounds.
UNC Biostatistics Michael R. Kosorok, Ph.D. Department of Biostatistics Department of Biostatistics The University of North Carolina at Chapel Hill.

UNC Biostatistics Michael R. Kosorok, Ph.D. Department of Biostatistics Department of Biostatistics The University of North Carolina at Chapel Hill.
Faculty Salary Equity Study University of North Carolina at Chapel Hill Faculty Council Report November 1, 2002.

Faculty Salary Equity Study University of North Carolina at Chapel Hill Faculty Council Report November 1, 2002.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Why the North of England and Why Leeds Sue Hunter International Office University of Leeds.

Why the North of England and Why Leeds Sue Hunter International Office University of Leeds.
WHI Extension 2010-2015 New Directions for Environmental Studies in the Women’s Health Initiative Annual WHI Investigator Meeting Washington, DC Friday.

WHI Extension New Directions for Environmental Studies in the Women’s Health Initiative Annual WHI Investigator Meeting Washington, DC Friday.
Randomized Comparison of High-Dose Oral Vitamins versus Placebo in the Trial to Assess Chelation Therapy (TACT) Gervasio A. Lamas, MD, FACC Professor of.

Randomized Comparison of High-Dose Oral Vitamins versus Placebo in the Trial to Assess Chelation Therapy (TACT) Gervasio A. Lamas, MD, FACC Professor of.
Mark Your Calendar, Reserve Your Seat and Tell Your Colleagues: The CVRN Board Certification Review Course is Coming to: Come for the Best Review of Clinical.

Mark Your Calendar, Reserve Your Seat and Tell Your Colleagues: The CVRN Board Certification Review Course is Coming to: Come for the Best Review of Clinical.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.

Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.

Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
1 John Hopkins University (Baltimore, Maryland) 2 Georgia Institute of Technology (Atlanta, Georgia) 3 Duke University (Durham, North Carolina) 4 University.

1 John Hopkins University (Baltimore, Maryland) 2 Georgia Institute of Technology (Atlanta, Georgia) 3 Duke University (Durham, North Carolina) 4 University.
Kenneth W. Mahaffey, Zhen Huang, Pierluigi Tricoci, Frans Van de Werf, Harvey D. White, Paul W. Armstrong, Claes Held, Sergio Leonardi, Philip E. Aylward,

Kenneth W. Mahaffey, Zhen Huang, Pierluigi Tricoci, Frans Van de Werf, Harvey D. White, Paul W. Armstrong, Claes Held, Sergio Leonardi, Philip E. Aylward,
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in 2001 56 millions deaths worldwide in 2001 29% due to CV disease (~ 16.

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,

Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,
Presented December 5-6, 2015 by: Presented by: American College of Cardiovascular Nurses, American Board of Cardiovascular Medicine, and the NCH Healthcare.

Presented December 5-6, 2015 by: Presented by: American College of Cardiovascular Nurses, American Board of Cardiovascular Medicine, and the NCH Healthcare.

Similar presentations

Ads by Google